245 related articles for article (PubMed ID: 33597219)
1. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.
Caracciolo D; Riillo C; Ballerini A; Gaipa G; Lhermitte L; Rossi M; Botta C; Duroyon E; Grillone K; Gallo Cantafio ME; Buracchi C; Alampi G; Gulino A; Belmonte B; Conforti F; Golino G; Juli G; Altomare E; Polerà N; Scionti F; Arbitrio M; Iannone M; Martino M; Correale P; Talarico G; Ghelli Luserna di Rorà A; Ferrari A; Concolino D; Sestito S; Pensabene L; Giordano A; Hildinger M; Di Martino MT; Martinelli G; Tripodo C; Asnafi V; Biondi A; Tagliaferri P; Tassone P
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597219
[TBL] [Abstract][Full Text] [Related]
2. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
[TBL] [Abstract][Full Text] [Related]
3. A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia.
Bartels L; de Jong G; Gillissen MA; Yasuda E; Kattler V; Bru C; Fatmawati C; van Hal-van Veen SE; Cercel MG; Moiset G; Bakker AQ; van Helden PM; Villaudy J; Hazenberg MD; Spits H; Wagner K
Cancer Res; 2019 Jul; 79(13):3372-3382. PubMed ID: 31064847
[TBL] [Abstract][Full Text] [Related]
4. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113
[TBL] [Abstract][Full Text] [Related]
5. UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
Caracciolo D; Polerà N; Belmonte B; Conforti F; Signorelli S; Gulino A; Staropoli N; Tuccillo FM; Bonelli P; Juli G; Grillone K; Ascrizzi S; Cirillo M; Migale L; Ballerini A; Pelizon C; Di Martino MT; Tagliaferri P; Riillo C; Tassone P
Br J Haematol; 2024 Feb; 204(2):555-560. PubMed ID: 37963444
[TBL] [Abstract][Full Text] [Related]
6. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
[TBL] [Abstract][Full Text] [Related]
7. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
8. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
[TBL] [Abstract][Full Text] [Related]
9. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
10. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
11. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.
Rossi DL; Rossi EA; Cardillo TM; Goldenberg DM; Chang CH
MAbs; 2014; 6(2):381-91. PubMed ID: 24492297
[TBL] [Abstract][Full Text] [Related]
12. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
13. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
14. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
Front Immunol; 2021; 12():719116. PubMed ID: 34484225
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
[TBL] [Abstract][Full Text] [Related]
16. COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors.
Panchal A; Seto P; Wall R; Hillier BJ; Zhu Y; Krakow J; Datt A; Pongo E; Bagheri A; Chen TT; Degenhardt JD; Culp PA; Dettling DE; Vinogradova MV; May C; DuBridge RB
MAbs; 2020; 12(1):1792130. PubMed ID: 32684124
[TBL] [Abstract][Full Text] [Related]
17. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
18. A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors.
Yoon A; Lee S; Lee S; Lim S; Park YY; Song E; Kim DS; Kim K; Lim Y
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32143496
[TBL] [Abstract][Full Text] [Related]
19. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.
Hoseini SS; Guo H; Wu Z; Hatano MN; Cheung NV
Blood Adv; 2018 Jun; 2(11):1250-1258. PubMed ID: 29858209
[TBL] [Abstract][Full Text] [Related]
20. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N
Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
